antiandrogens/neoplasms

FIELD OF THE INVENTION Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. BACKGROUND OF

FIELD OF THE INVENTION Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. BACKGROUND OF

FIELD OF THE INVENTION Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspir- o[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. BACKGROUND OF

FIELD OF THE INVENTION Disclosed herein are methods of treating non-metastatic castration-resistant prostate cancer with an approved drug product containing an anti-androgen selected from the group consisting of enzalutamide, apalutamide and darolutamide. Also disclosed are methods of selling or

BACKGROUND OF THE INVENTION The present invention relates to native, site specifically mutated, and synthetic peptides comprising portions of the human androgen receptor and composition thereof. The invention also relates to antibodies raised against these peptides and polynucleotides encoding these

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to methods and materials for assessing prostate cancer therapies. 2. Description of Related Art Cancer is the second leading cause of human death next to coronary disease. Worldwide, millions of people die from

BACKGROUND OF THE INVENTION This invention relates to a new method of treatment for patients, i.e. men having prostatic cancer, which treatment involves a combination therapy of administering therapeutically effective amounts of a 5.alpha.-reductase inhibitor in combination with an antiandrogenic

FIELD OF THE INVENTION The present invention relates to low molecular weight compounds, useful as antiandrogens, and in particular as antiandrogens with low androgenic activity. The invention further relates to methods for inhibiting androgen receptors and in treating androgen receptor-mediated

BACKGROUND OF THE INVENTION I. Information Relating to Previous Squalamine Applications This invention relates to various methods for using squalamine. Squalamine, having the structure illustrated in FIG. 1, is an aminosterol which has been isolated from the liver of the dogfish shark, Squalus

TECHNICAL FIELD This invention relates to a method for the treatment of prostate cancer and a composition for the treatment of prostate cancer. This invention also relates to a method of treating prostate cancer that minimizes some of the undesirable side effects of the treatments. BACKGROUND OF THE

FIELD OF THE INVENTION The invention is generally directed to combination therapies including an antiandrogen or androgen antagonist and a polo-like kinase inhibitor for the treatment of cancer. BACKGROUND OF THE INVENTION Prostate cancer is the most frequently diagnosed non-skin related cancer and

FIELD OF THE INVENTION The invention is generally directed to combination therapies including an antiandrogen or androgen antagonist and a polo-like kinase inhibitor for the treatment of cancer. BACKGROUND OF THE INVENTION Prostate cancer is the most frequently diagnosed non-skin related cancer and

FIELD Provided herein are compositions, systems, kits, and methods for treating cancer in a subject with androgen receptor positive cancer cells by sensitizing such cancer cells with anti-androgen receptor therapy (e.g., Enzalutamide or anti-androgen antibody), and then treating with radiation

CROSS-REFERENCE TO RELATED APPLICATIONS This Application is related to the following copending U.S. patent applications: Ser. Nos. 636,883, filed Aug. 2, 1984; 699,702, filed Feb. 8, 1985, now U.S. Pat. No. 4,666,885; 699,710, filed Feb. 8, 1985; and 699,711, filed Feb. 8, 1985, now U.S. Pat. No.

BACKGROUND OF THE INVENTION This invention relates to a combination therapy for selected sex steroid dependent cancers in susceptible warm-blooded animals including humans comprising administering to such animals whose hormone output of their testes or ovaries, respectively, is blocked a